George Georgiou

Technologies

• Broadly neutralizing human mAbs targeting the SARS‑CoV‑2 spike protein
• Advanced techniques for generating antigen-specific antibodies
• Pharmacologically optimized human kynureninase variants for cancer treatment
• Therapeutic applications of engineered L-Cyst(e)ine-degrading enzymes
• Engineered enzymes for enhanced kynurenine degradation in cancer therapy​​
• Enhanced cancer treatment through methionine depletion
• Biotechnological approach for cancer treatment through kynurenine depletion using engineered enzymes​​​​​
• Biotechnological platform for engineering enzymes to degrade L‑Cyst(e)ine for cancer therapy
• Methodology for high-throughput sequencing of paired antibody transcripts from B cells
• Modified kynureninase enzymes for cancer therapy
• Antibody and T-cell receptor sequencing for identifying cancer-specific immune receptors